一分钟看懂
这是一项关于结直肠癌的II 期研究，登记的药物或干预包括Tislelizumab，当前状态为招募中。登记地点显示中国New York、Idi Araba、Ile-Ife有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tislelizumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Memorial Sloan Kettering Cancer Center · New York
- Lagos University Teaching Hospital · Idi Araba
- Obafemi Awolowo University Teaching Hospital · Ile-Ife
公开的入选条件
- * Age 18 years or older on date of signing informed consent
- * ECOG performance status of 0 or 1
- * Negative pregnancy test done within 72 hours prior to start of treatment for women of childbearing potential.
- Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of tislelizumab They must also have a negative urine or serum pregnancy test result ≤ 7 days
- The Clinical Trials Facilitation Group recommendations related to contraception and pregnancy testing in clinical studies include the use of highly effective forms of birth control (Clinical Trials Facilitation Group 2014). These methods include the following:
- Oral, intravaginal, or transdermal combined (estrogen- and progestogen-containing) hormonal contraception associated with the inhibition of ovulation
- Oral, injectable, implantable progestogen-only hormonal contraception associated with the inhibition of ovulation Note: Oral birth control pills are not considered a highly effective form of birth control, and if they are selected, they must be used with a sec
- An intrauterine device
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06529523；登记信息更新于 2026-09-17。